3 days Ago aprott/iStock via Getty Images Novo Nordisk ( NVO ) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery disease (PAF) achieved its primary goal. Citing full results.
